Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66


Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.

Kim M, Nitschké M, Sennino B, Murer P, Schriver BJ, Bell A, Subramanian A, McDonald CE, Wang J, Cha H, Bourgeois-Daigneault MC, Kirn DH, Bell JC, De Silva N, Breitbach CJ, McDonald DM.

Cancer Res. 2018 Feb 15;78(4):922-937. doi: 10.1158/0008-5472.CAN-15-3308. Epub 2017 Dec 19.


VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.


A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.

Breitbach CJ, Moon A, Burke J, Hwang TH, Kirn DH.

Methods Mol Biol. 2015;1317:343-57. doi: 10.1007/978-1-4939-2727-2_19.


Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH.

Curr Opin Virol. 2015 Aug;13:49-54. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Review.


The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J.

Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Review.


Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.

Cripe TP, Ngo MC, Geller JI, Louis CU, Currier MA, Racadio JM, Towbin AJ, Rooney CM, Pelusio A, Moon A, Hwang TH, Burke JM, Bell JC, Kirn DH, Breitbach CJ.

Mol Ther. 2015 Mar;23(3):602-8. doi: 10.1038/mt.2014.243. Epub 2014 Dec 22.


First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.

Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL.

Mol Ther. 2015 Jan;23(1):202-14. doi: 10.1038/mt.2014.194. Epub 2014 Oct 8.


Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.

Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, Lee JW, Kim SG, Kang DH, Bell JC, Park BH, Kirn DH, Hwang TH.

Sci Transl Med. 2013 May 15;5(185):185ra63. doi: 10.1126/scitranslmed.3005361.


Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.

Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.


Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.

Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7.


Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells.

Tai LH, de Souza CT, Bélanger S, Ly L, Alkayyal AA, Zhang J, Rintoul JL, Ananth AA, Lam T, Breitbach CJ, Falls TJ, Kirn DH, Bell JC, Makrigiannis AP, Auer RA.

Cancer Res. 2013 Jan 1;73(1):97-107. doi: 10.1158/0008-5472.CAN-12-1993. Epub 2012 Oct 22.


The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.


Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH.

Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.


A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma.

Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH.

Mol Ther. 2011 Oct;19(10):1913-22. doi: 10.1038/mt.2011.132. Epub 2011 Jul 19.


Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.

Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. Review.


Redemption for the field of oncolytic virotherapy.

Kirn DH.

Mol Ther. 2011 Apr;19(4):627-8. doi: 10.1038/mt.2011.45. No abstract available.


Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH.

Mol Ther. 2011 Jun;19(6):1170-9. doi: 10.1038/mt.2011.39. Epub 2011 Mar 22.


Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Huang B, Sikorski R, Kirn DH, Thorne SH.

Gene Ther. 2011 Feb;18(2):164-72. doi: 10.1038/gt.2010.121. Epub 2010 Aug 26.


Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):85-9. doi: 10.1016/j.cytogfr.2010.02.001. Epub 2010 May 15. Review.


A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC.

Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13.


Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.

De Silva N, Atkins H, Kirn DH, Bell JC, Breitbach CJ.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):135-41. doi: 10.1016/j.cytogfr.2010.02.007. Epub 2010 Mar 24. Review.


Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.

Lee JH, Roh MS, Lee YK, Kim MK, Han JY, Park BH, Trown P, Kirn DH, Hwang TH.

Cancer Gene Ther. 2010 Feb;17(2):73-9. doi: 10.1038/cgt.2009.50. Epub 2009 Jul 24.


Targeted genetic and viral therapy for advanced head and neck cancers.

Huang PI, Chang JF, Kirn DH, Liu TC.

Drug Discov Today. 2009 Jun;14(11-12):570-8. doi: 10.1016/j.drudis.2009.03.008. Epub 2009 Mar 17. Review.


Oncolytic virotherapy for advanced liver tumours.

Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn DH, Liu TC.

J Cell Mol Med. 2009 Jul;13(7):1238-47. doi: 10.1111/j.1582-4934.2008.00563.x. Epub 2008 Oct 23. Review.


Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Kirn DH, Thorne SH.

Nat Rev Cancer. 2009 Jan;9(1):64-71. doi: 10.1038/nrc2545. Review.


Development of targeted oncolytic virotherapeutics through translational research.

Liu TC, Hwang TH, Bell JC, Kirn DH.

Expert Opin Biol Ther. 2008 Sep;8(9):1381-91. doi: 10.1517/14712598.8.9.1381 . Review.


Oncolytic adenoviruses for cancer gene therapy.

Liu TC, Thorne SH, Kirn DH.

Methods Mol Biol. 2008;433:243-58. doi: 10.1007/978-1-59745-237-3_15.


The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Liu TC, Hwang T, Park BH, Bell J, Kirn DH.

Mol Ther. 2008 Sep;16(9):1637-42. doi: 10.1038/mt.2008.143. Epub 2008 Jul 15.


Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

Liu TC, Hwang TH, Bell JC, Kirn DH.

Mol Ther. 2008 Jun;16(6):1006-8. doi: 10.1038/mt.2008.70. No abstract available.


Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, Oh SY, Han SY, Yoon JH, Hong SH, Moon A, Speth K, Park C, Ahn YJ, Daneshmand M, Rhee BG, Pinedo HM, Bell JC, Kirn DH.

Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Erratum in: Lancet Oncol. 2008 Jul;9(7):613.


Enhancing poxvirus oncolytic effects through increased spread and immune evasion.

Kirn DH, Wang Y, Liang W, Contag CH, Thorne SH.

Cancer Res. 2008 Apr 1;68(7):2071-5. doi: 10.1158/0008-5472.CAN-07-6515.


Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.

Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M; GRACES Clinical Trial Consortium.

Gynecol Oncol. 2008 May;109(2):174-81. doi: 10.1016/j.ygyno.2008.01.005. Epub 2008 Mar 7.


Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.

Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH.

PLoS Med. 2007 Dec;4(12):e353.


Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963.

Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F, Brown C, Werier J, Cho JH, Lee DE, Wang Y, Bell J, Kirn DH.

J Clin Invest. 2007 Nov;117(11):3350-8.


From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development.

Crompton AM, Kirn DH.

Curr Cancer Drug Targets. 2007 Mar;7(2):133-9. Review.


Vaccinia virus and oncolytic virotherapy of cancer.

Thorne SH, Hwang TH, Kirn DH.

Curr Opin Mol Ther. 2005 Aug;7(4):359-65. Review.


The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?

Thorne SH, Bartlett DL, Kirn DH.

Curr Gene Ther. 2005 Aug;5(4):429-43. Review.


Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.

Thorne SH, Kirn DH.

Expert Opin Biol Ther. 2004 Aug;4(8):1307-21. Review.


Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite.

Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, Patrick G.

Int J Oncol. 2004 Jul;25(1):173-8.


Replication-selective oncolytic adenoviruses.

Halldén G, Thorne SH, Yang J, Kirn DH.

Methods Mol Med. 2004;90:71-90. No abstract available.


Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.

Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Lecluse Y, van Beusechem VW, Gerritsen WR, Kirn DH, Vassal G.

Br J Cancer. 2003 Aug 4;89(3):577-84.


A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM.

Clin Cancer Res. 2003 Feb;9(2):555-61.


Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.

Warren RS, Kirn DH.

Surg Oncol Clin N Am. 2002 Jul;11(3):571-88, vi. Review.


Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB.

J Clin Oncol. 2002 Mar 15;20(6):1562-9.


Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts.

Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ, Bressac De-Paillerets B, Barrois M, Feunteun J, Kirn DH, Vassal G.

Cancer Res. 2002 Feb 1;62(3):764-72.


Modeling and analysis of a virus that replicates selectively in tumor cells.

Wu JT, Byrne HM, Kirn DH, Wein LM.

Bull Math Biol. 2001 Jul;63(4):731-68.


Supplemental Content

Support Center